Stem‑cell Heart Patches Improve Outcomes in 12 of 20 Patients
Cardiac "remuscularization" for treating severe heart failure with patched heart muscle derived from stem cells (a biological ventricular assist device) successful in 12 of 20 patients @NEJM https://t.co/mAwgj2rAwE https://t.co/3ogxaJFDE0 https://t.co/J1ozMsS4Oh
New Stem Cell Subtype Remembers Inflammation, Impacts Prognosis
New @nature. Discovery of a new subtype of blood stem cells—HSC-iM—which have memory to previous inflammation, such as with Covid or aging, and prognostic significance https://t.co/hRfp5xnJGj
Antiviral Valganciclovir Extends GBM Survival to 5 Years
🧠 GBM patients on continuous valganciclovir survived 56.4 months — nearly 5 years — vs. the typical 12–15. Years ago, Thomas Seyfried told me that CMV damages mitochondria and drives tumor initiation and growth. This NEJM study validated that insight in a...
First Universal Protein Model Promises New Therapies
Today Biohub is sharing a major scientific advance: our first world model for protein biology. This system can help scientists discover and design proteins that will hopefully lead to new medical therapies.
Paricalcitol Shows Promise in Metastatic Pancreatic Cancer
A small randomized trial in patients with metastatic pancreatic cancer found benefit for paricalcitol, a Vitamin D analog https://t.co/CDnIwm0xeo Good @salkinstitute explainer https://t.co/QgEKHiquIa https://t.co/m32CFTInJA
New DNA Assembly Method Bridges Design and Synthesis
A new DNA assembly method closes the gap between generative genome design and lab-scale synthesis. https://spectrum.ieee.org/faster-dna-synthesis-sidewinder?share_id=9503681
Two Decades of Evolving ASCO Clinical Trial Trends
Trends and characteristics of clinical trials presented in ASCO plenary sessions (2011–2025) - Overheu #ASCO26 Abstract # 11024, Poster Bd # 7 https://t.co/JYI0LY7FbU #ClinicalTrials #ctsm @ASCO
Ivonescimab Shows
#ASCO26 LBA4 - Zhiwei - Ivonescimab + chemo vs tislelizumab + chemo 1L sq NSCLC - Ph3 HARMONi-6 [May 31, 2026] Zhiwei et al. https://t.co/oWEeVo2oyq #NCT05840016 #lcsm #ImmunoOnc
Len
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol https://t.co/hXxlFINejC #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm https://t.co/Gx8qHe4PLo
Single VERVE-102 Dose Slashes PCSK9 and LDL
we live in the future - the next step is designing large gene insertions and fine scale editing with AI 👀 @ProfluentBio “One dose of VERVE-102 (in vivo base editor) led to dose-dependent, substantial, and sustained reductions in PCSK9 and...
Lilly's Verve Gene Editor Cuts Cholesterol, but Delays Loom
Eli Lilly $LLY says Verve’s gene editor lowers cholesterol levels in early, but development timelines have slipped. https://t.co/fuJOPyDwQb via @Jasonmmast
Tri‑complex RAS Inhibitors: 40k Compounds,
Came across this great talk from $RVMD's Adrian Gill on @drughunter_com about the development of probably one of the most important oncology drug classes in history : Tri-complex RAS inhibitors. It's not too technical so non-chemists can follow as well. Synthesized...
Money, Patience, Intent—And Animal Models Drive Drug Discovery
After we showed that we can discover a drug in the UAE from scratch, many countries and their R&D organizations started reaching out with the offers "set up a site in our country and gain access to our wonderful population...
Cancer Immunotherapy Surge: Emerging Treatments and Future Outlook
I wrote about the remarkable proliferation of cancer immunotherapies, and what's in store https://t.co/od4MeFMGik https://t.co/5jI10LLbLq
Epigenetic Editing Advances Toward Safer Gene Therapies
1/Here is an excellent article by @TheEconomist which sheds light on a new and promising Gene Editing modality called EpiGenetic Editing. Unlike its older and more clinically mature Gene Editing “siblings” - CRISPR, Base Editing, Prime Editing and RNA Editing,...
AI Models Slash Biomanufacturing Delays, Save $100M Monthly
Abinitio Bio is building the foundation models for biomanufacturing, turning 6-18 month process decisions into hours of compute and saving pharma $100M+ per month of delay on blockbusters. Congrats on the launch, @DanielMukasa1! https://t.co/r5nz5gVKPM https://t.co/HgPPRDs7Ew
Semaglutide Drives Significant Fat Loss in Bariatric Non‑responders
For patients who did not respond well to bariatric surgery, semaglutide shifted weight loss far beyond placebo over 68 weeks. Most of that loss came from body fat rather than muscle. obesity
Quality Control: The Key to Stunning Plots
1/ You want beautiful volcano plots. Striking heatmaps. Big discoveries. But before the analysis, comes one boring step you can't skip: QC. It’ll save your science. 🧵 https://t.co/PBnehqINrR
High Neutralizing Antibodies Block Infection and Transmission
1/n But I’ve never “dodged the question,” it’s straightforward: when the levels of virus neutralizing antibodies are high, enough VNAs enter the throat and nose to stop infection and transmission. In early 2021, the Israeli’s showed with the Pfizer vaccine...
Genomics Predict Venetoclax Response in T(
Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax [Dec 7, 2024] @MKaddouraMD et al. @lbaughn #ASH24 Abst 249 https://t.co/TLon5bCQ3i #mmsm #PrecisionMedicine
New Trial Compares Dara‑Bor‑Dex vs Cy‑Bor‑Dex for Myeloma‑Induced Kidney
EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc
IMMX Secures $150M at $8.94 to Fund NXC-201
$IMMX prices $150M underwritten offering at $8.94/share, with proceeds expected to fund continued NXC-201 development and extend operational runway into mid-2028. Morgan Stanley and BofA Securities are leading the deal. Read more: https://t.co/QxQsiNNXbz
First FDA‑approved Longevity Drug Targets Dogs First
NEW Exclusive Interview: This miracle pill could make dogs live longer, with Celine Halioua, Founder & CEO of Loyal @celinehalioua is building the first drug ever FDA-approved for lifespan extension itself — starting with dogs. We sat down on Onward to...
AI‑Designed PE8 Editors Boost Prime Editing Efficiency
Today in @NatureBiotech we report a new suit of PE8 prime editor proteins. PE8 variants were developed from laboratory-evolved PE6 proteins using AI-guided protein redesign. This approach combines recent advances in computational protein design and directed evolution to increase prime...
Retatrutide Delivers Record 28% Weight Loss, Raises Safety Concerns
Retatrutide, a triple receptor drug for GLP-1, GIP, and glucagon, is the most powerful weight loss drug yet. A significant issue is too much weight loss among the trial participants. New randomized trial results announced today with 28% body weight...
Retatrutide Delivers up to 30% Weight Loss in Phase 3 Trials
Retatrutide just delivered some very impressive phase3 results for $LLY at 4mg, 9mg and 12mg -- https://t.co/7sKbaDoInq Retatrutide is their GLP-3 ie triple agonist which hits the GLP, GIP and Glucagon receptors. At the primary endpoint of 80 weeks... patients on 4mg,...
Algae‑Powered Robot Swarms Heal Wounds Using Light
Living #Robot swarms built from algae can split, merge, and target wounds with light by Neetika Walter @IntEngineering Learn more: https://t.co/eFL1uXG9hg #MedTech #Healthcare #HealthTech #Tech #TechForGood https://t.co/P2jlormizm
IL-6 Blocker Shows Promise for Treating Depression
Would depression respond to an anti-inflammation drug (interleukin-6 blocker)? A small pilot, placebo-controlled randomized trial suggests this might be possible https://t.co/zKO76yvRAo https://t.co/e8K9YLEAQj
Longevity Biotech Matures: Precise Indication‑Focused Drug Development
The longevity biotechnology field is coming of age in the best possible way. A recent analysis captures how the sector has learned to speak pharma’s language fluently—moving from broad claims about “slowing aging” to precise, indication-focused drug development with conventional endpoints,...
Activist Targets 80%-Down Biopharma at Cash‑Discount
Clinical-stage biopharma down 80% after a failed trial, now at a massive discount to net cash Biopharma activist just took a sizeable position via 13G. Mgmt has prior wind-down and sell experienc. Clear path: halt trial, strategic review, re-rate higher. Full pitch on...
Parabilis Raises $800M, Eyes IPO to Tackle Undruggable Targets
After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets https://t.co/hKprr9rkJ4 @ByJonGardner $PBLS #biotech #IPO
BARDA Ships Experimental Ebola Antibody to Protect High‑risk Americans
BARDA is coordinating shipment of an experimental antibody treatment for potential use in high-risk Americans exposed to #ebola, HHS tells CNN While they didn't name the treatment, Mapp's MBP134 has shown activity in animal studies against Bundibugyo strain
TMDX Poised for Massive Organ Transport Growth by 2032
I spent some quality time today with the $TMDX team at their HQ in Andover, MA. I’ll share some deeper thoughts over the next few days including my bear case, base case, bull case and super bull case for the...
Multi‑Agent AI Boosts Biomedical Discovery Across Diseases
A big day for multi-agent AI to accelerate biomedical discovery, hypothesis generation, designing experiments with proof points of new candidate drugs (cancer, fibrosis, macular degeneration, antimicrobial resistance, and more) 2 @Nature reports @GoogleDeepMind @FutureHouseSF https://t.co/u1EYvJ05VJ https://t.co/8DpAolom0F
Colossal's 3D‑Printed Chick Incubator:
Colossal Biosciences has grown baby chicks inside 3D-printed plastic containers coated with a silicone-based membrane that mimics an eggshell's oxygen exchange — a meaningful step, but scientists say the company is overselling it.
Relay Drug Shows Early Promise for Rare Vascular Diseases
Relay drug shows early promise against rare blood vessel diseases https://t.co/WUJw7M1QDc $RLAY + 10% $NVS $OKUR
UC Maintenance Trials Drag On, Costs Soar
So uhhh, how long are these mega-expensive P3 UC maintenance studies going to have to be run for $SYRE? If only drug arm induction responders go onto maintenance (as is convention in P3 UC studies), how long do you need to...
Single VSV Vaccine Dose Shields Monkeys From Bundibugyo Ebola
Single Immunization With a Monovalent Vesicular Stomatitis Virus–Based Vaccine Protects Nonhuman Primates Against Heterologous Challenge With Bundibugyo ebolavirus https://t.co/ShMm7CSW0I
Uridine and Pyruvate Preserve T‑Cell Proliferation During Antibiotic Treatment
Uridine and pyruvate protect T cells’ proliferative capacity from mitochondrial toxic antibiotics: a clinical pilot study https://t.co/6NyObkztoA
Kazia’s Paxalisib Shows >50% CTC Drop, Early Responses
Kazia Therapeutics ($KZIA) is a catalyst-driven setup centered on upcoming ASCO data from their Paxalisib drug development platform. The update is following earlier disclosures from their ongoing Phase 1b ABC-Pax study evaluating paxalisib in metastatic triple-negative breast cancer (TNBC) showing...
FDA Greenlights Enhertu for Early HER2‑positive Breast Cancer
#AZN Enhertu approved by US FDA both before and after surgery for treating patients with HER2-positive early breast cancer.
Zusduri Demonstrates Real-World Efficacy for Low-Grade UTUC
UroGen’s Zusduri shows strong real-world results for low-grade upper tract urothelial cancer, matching clinical trial efficacy. A promising kidney-sparing option, though durability and reimbursement remain key hurdles. Urology
AI Predicts Tumor Gene Expression From Slides in Minutes
An AI tool predicted spatial gene expression across tumors from digital biopsy slide images in minutes, offering a far less costly alternative to conventional profiling. cancer
Expert Wei Debunks PRME Failure Claims with CRISPR Insight
Here is a great overview by one of the most educated & knowledgeable people on 𝕏 and a personal friend - @zhaoweiasu, in which he rebutted the argument that $PRME has failed to deliver on its business model. As an...
CRISPR Shifts to DNA‑guided RNA Targeting
Expanding the CRISPR genome editing toolkit: A flip from RNA-guided DNA targeting to DNA-guided RNA targeting @NatureBiotech https://t.co/GxKVthgbxh https://t.co/UIifna0nsF https://t.co/2ZB1eJzpCe
Prime and Base Editing Complement, Not Replace, Each Other
The common theme that “Prime Editing $PRME will eventually replace Base Editing $BEAM and make it obsolete” is completely wrong. An example for their irreplaceable and even complementary rule can be seen in an excellent research published by @eyeMacLaren which...
Repeated Psilocybin Doses Show Safety, Promise for OCD
A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive–compulsive disorder 🍥"Administration of up to eight doses of psilocybin in a clinical research setting appears to be safe and potentially effective for patients with OCD. Larger trials...
New GLP‑1 Scale Target Tackles Aging Inflammation
Love what Kristen at BioAGE is doing (see the link to Fierce Pharma by Will Maddox in the comments). We also have a portfolio of BIC NLRP3 in Phase I and IND-enabling. Love this target with all my heart and...
FDA CDER Acting Director Tracy Hoeg Set to Leave
FDA Center for Drug Evaluation & Research (CDER) Acting Director Tracy Beth Hoeg expected to depart from agency - Reuters
Biotech Execs Rally for Pazdur as Takeda Cuts 4,500 Jobs
#Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers https://t.co/q8ENAYhAJF $ALMS $TAK $AZN $ONC